Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Login   

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 1341 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

CASE REPORT Table of Contents   
Year : 1994  |  Volume : 5  |  Issue : 3  |  Page : 371-373
Is erythropoietin safe in haemodialysis patients with multiple myeloma ?

Department of Nephrology and Dialysis Al Hada Armed Forces Hospital, Taif, Saudi Arabia

Correspondence Address:
Magdi Hussein
Department of Nephrology and Dialysis, Al Hada Armed Forces Hospital, P.O. Box 1347, Taif
Saudi Arabia
Login to access the Email id

PMID: 18583767

Rights and Permissions

The use of recombinant human erythropoietin (rHuEpo) for the treatment of anemia of end-stage renal disease (ESRD) is now well established. There have also been reports about its use in treating the anemia of other diseases including multiple myeloma (MM). Some concern about the usage of rHuEpo in patients with MM has been raised by studies reporting worsening of myeloma activity after starting this drug. However, other studies have reported its safety in patients with MM. We report here a patient on maintenance haemodialysis, not known to have MM who developed symptoms related to this disease four months after starting rHuEpo. Although we might speculate that the onset of symptoms was coincidental and not causally related to rHuEpo, we recommend close monitoring of the disease activity in patients with MM receiving rHuEpo.

Print this article  Email this article

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded187    
    Comments [Add]    

Recommend this journal